Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

MASTER SCREENING STUDY TO DETERMINE INDIVIDUALS WITH POTENTIAL TRIAL ELIGIBILITY FOR ALZHEIMER'S DISEASE STUDIES AS ASSESSED BY BIOMARKER STATUS AND COGNITION

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1030250323

Enrollment

13000

Registered

2025-08-29

Start date

2025-09-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzhimer's disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion criteria

Exclusion criteria: -Dependency in basic activities of daily living (bADLs) due to cognitive impairment -Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted) -Any self-reported evidence or known diagnosis of a neurological or neurodegenerative condition that may lead to cognitive impairment other than AD -History of severe, clinically significant central nervous system trauma -Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Design outcomes

Primary

Measure	Time frame
other -Concentration of pTau217 in Blood on Day1 -Cognitive score in ISLT on Day 1	—

Secondary

Measure	Time frame
other -	—

Countries

Australia, Canada, China, Denmark, Japan, Poland, Taiwan, United States

Contacts

Public Contactinformation Clinical trials

Chugai Pharmaceutical Co., Ltd.

clinical-trials@chugai-pharm.co.jp+81-120189706

Outcome results